StageII(high risk) and stageIII resectable colorectal cancer
Conditions
Interventions
Capecitabine 5-days on/ 2-days off schedule
Capecitabine conventional schedule
Sponsors
Wakayama Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Histopathological diagnosis of colorectal cancer 2.Postoperative adjuvant chemotherapy is scheduled after colorectal cancer resection in Stage II and III. 3. Chemotherapy of capecitabine is scheduled as postoperative adjuvant chemotherapy. 4.Age:20-80 years old 5.ECOG Performance Status 0-1 6. i)WBC more than 3000/mm3, ii) neutrophil more than 1500/mm3, iii) Platelet more than 10x10^4/mm3, iv) Hb more than 9g/dL, v) TBil less than 1.5mg/dL, vi) AST and ALT less than 100IU/L vii) Cr less than 1.5mg/dL, 7.chemotherapy has not been administered for the target disease 8.informed consent
Exclusion criteria
Exclusion criteria: 1. duplicated active cancer 2. history of severe drug hypersensitivity 3. clinically problematic infection 4. it is judged that registration in this study is difficult due to clinically problematic mental / neurological diseases 5. any of the following complications i) diabetes with poor control ii) hypertension with poor control iii) interstitial pneumonia or pulmonary fibrosis iv) intestinal palsy or intestinal obstruction v) clinically problematic heart disease 6. already undergoing other chemotherapy before and after surgery 7. temporary ileostomy/colostomy closure is scheduled and the administration period of continuous 24 weeks is interrupted for a long time (8) Other cases that the doctor in charge judged unsuitable for safely carrying out this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| feasibility | — |
Countries
Japan
Contacts
Public ContactYuki Mizumoto
Wakayama Medical University Second Department of Surgery
Outcome results
None listed